- Topics
- Webcasts & Training
- Events
This timely event will cover the regulatory shift in the U.S. on ESG-centered disclosure; calls for a global, standardized reporting framework; preventing greenwashing in one’s marketing and public relations efforts; third-party risk management; and technology solutions in ESG reporting, monitoring, and benchmarking contexts.
Register
- Resource Library
- Special Reports
- Video
- Membership
Learn from the latest headlines and protect your company today
- Amazon discloses record-shattering $887M GDPR fine
- Compliance ramifications of proposed $26B opioid deal for pharma industry
- Report: Deficient risk culture at Credit Suisse contributed to Archegos collapse
- Ex-KPMG partners barred by SEC over cheating scandal roles
Individual Corporate
Close menu
- Home
-
Topics
- Back to parent navigation item
- Topics
- Accounting & Auditing
- AML
- Anti-Bribery
- Anti-Corruption
- Boards & Shareholders
- Cyber-Security
- Data Privacy
- ESG/Social Responsibility
- Ethics & Culture
- Europe
- Financial Services
- GRC Appointments
- Internal Controls
- Regulatory Enforcement
- Regulatory Policy
- Risk Management
- Sanctions
- Surveys & Benchmarking
- Supply Chain
- Technology
- Third Party Risk
- Whistleblowers
- Compensation
- GDPR
- Internal Investigations
- Opinion
- Training
- Culture
- GRC Announcements
- My Compliance Library
- Ask Amii Mailbag
- Nailed It or Failed It
- Risk and Regulatory Compliance
- Accounting and Audit
- Webcasts & Training
- Events
- Resource Library
- Special Reports
- Video
- Membership
FTC gearing up for aggressive oversight of antitrust, M&A
By Jaclyn Jaeger2021-04-13T20:05:00
With a changing of the guard, the Federal Trade Commission is undergoing some major restructuring on the antitrust front. All told, it’s not just Big Tech and pharmaceutical companies that should be on alert.
WELCOME TO OUR OPEN HOUSE – LOG IN TO CONTINUE READING FOR FREE
If you are already a registered user or a member, SIGN IN now.